Alector(US:ALEC) ZACKS·2025-11-07 00:26Core Insights - Alector reported a quarterly loss of $0.34 per share, better than the Zacks Consensus Estimate of a loss of $0.42, marking an earnings surprise of +19.05% [1] - The company generated revenues of $3.26 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 24.19%, but down from $15.34 million year-over-year [2] - Alector's stock has underperformed, losing approximately 33.6% since the beginning of the year, while the S&P 500 has gained 15.6% [3] Financial Performance - Over the last four quarters, Alector has surpassed consensus EPS estimates four times and topped revenue estimates three times [2] - The current consensus EPS estimate for the upcoming quarter is -$0.41 on revenues of $3 million, and for the current fiscal year, it is -$1.57 on revenues of $17.15 million [7] Industry Context - Alector operates within the Medical - Biomedical and Genetics industry, which is currently ranked in the top 41% of over 250 Zacks industries [8] - The industry’s performance can significantly impact Alector's stock performance, with research indicating that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8] Future Outlook - The sustainability of Alector's stock price movement will largely depend on management's commentary during the earnings call and future earnings expectations [3][4] - The estimate revisions trend for Alector was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6]